• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT Trial.

作者信息

Yan Hongmei, Karthikeyan Hridhay, Fan Wenjun, Yang Qin, Wong Nathan D

机构信息

Mary and Steve Wen Cardiovascular Division, Department of Medicine, University of California, Irvine, California, USA; Division of Endocrinology, Department of Medicine, University of California, Irvine, California, USA; Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.

Mary and Steve Wen Cardiovascular Division, Department of Medicine, University of California, Irvine, California, USA.

出版信息

JACC Adv. 2025 Jun;4(6 Pt 2):101773. doi: 10.1016/j.jacadv.2025.101773. Epub 2025 May 21.

DOI:10.1016/j.jacadv.2025.101773
PMID:40402121
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12277595/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b45/12277595/92231cba5c72/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b45/12277595/92231cba5c72/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2b45/12277595/92231cba5c72/gr1.jpg

相似文献

1
U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT Trial.司美格鲁肽在SELECT试验中的美国适用人群及可预防的心血管、糖尿病和肾脏结局
JACC Adv. 2025 Jun;4(6 Pt 2):101773. doi: 10.1016/j.jacadv.2025.101773. Epub 2025 May 21.
2
Eligibility for and practical implications of Semaglutide in overweight and obese patients with acute coronary syndrome.司美格鲁肽在急性冠状动脉综合征超重和肥胖患者中的适用性及实际意义。
Int J Cardiol. 2025 Mar 15;423:133028. doi: 10.1016/j.ijcard.2025.133028. Epub 2025 Jan 29.
3
Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.司美格鲁肽对比安慰剂在射血分数轻度降低或保留的心衰患者中的疗效：SELECT、FLOW、STEP-HFpEF 和 STEP-HFpEF DM 随机试验的汇总分析。
Lancet. 2024 Sep 7;404(10456):949-961. doi: 10.1016/S0140-6736(24)01643-X. Epub 2024 Aug 30.
4
Is semaglutide cost-effective at closing the gap for Aboriginal and Torres Strait Islander Australians with cardiovascular disease and obesity without type 2 diabetes?
Intern Med J. 2025 Jul 22. doi: 10.1111/imj.70160.
5
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.司美格鲁肽：治疗心血管-肾脏-代谢综合征的关键药物。
Future Cardiol. 2025 Jul;21(9):663-683. doi: 10.1080/14796678.2025.2511412. Epub 2025 Jun 3.
6
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
7
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.司美格鲁肽对 2 型糖尿病患者慢性肾脏病的影响。
N Engl J Med. 2024 Jul 11;391(2):109-121. doi: 10.1056/NEJMoa2403347. Epub 2024 May 24.
8
Allocation of Semaglutide According to Coronary Artery Calcium and BMI: Applying the SELECT Trial to MESA.根据冠状动脉钙化和体重指数分配司美格鲁肽：将SELECT试验应用于多族裔动脉粥样硬化研究（MESA）
JACC Cardiovasc Imaging. 2025 Apr;18(4):451-461. doi: 10.1016/j.jcmg.2024.10.004. Epub 2025 Jan 8.
9
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.持续每周皮下注射司美格鲁肽与安慰剂对超重或肥胖成年人体重维持的影响：STEP 4 随机临床试验。
JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224.
10
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial.司美格鲁肽对 FLOW 试验中糖尿病和慢性肾脏病合并心力衰竭结局的影响。
J Am Coll Cardiol. 2024 Oct 22;84(17):1615-1628. doi: 10.1016/j.jacc.2024.08.004. Epub 2024 Aug 30.

引用本文的文献

1
Metabolomic profiling reveals interindividual metabolic variability and its association with cardiovascular-kidney-metabolic syndrome risk.代谢组学分析揭示个体间的代谢变异性及其与心血管-肾脏-代谢综合征风险的关联。
Cardiovasc Diabetol. 2025 Aug 1;24(1):315. doi: 10.1186/s12933-025-02881-8.
2
Advancing Preventive Cardiology: Innovations, Care Pathways, Global Challenges, and the Future of Cardiovascular Health Across the Life Course.推进预防心脏病学：创新、护理路径、全球挑战以及一生中心血管健康的未来。
JACC Adv. 2025 Jun;4(6 Pt 2):101868. doi: 10.1016/j.jacadv.2025.101868.

本文引用的文献

1
National and State Estimates of SELECT Trial Eligibility and Its Public Health Impact in the US.美国SELECT试验资格的全国和州估计及其对公共卫生的影响。
JAMA Netw Open. 2024 Jul 1;7(7):e2420105. doi: 10.1001/jamanetworkopen.2024.20105.
2
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
3
Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey.
基于SELECT试验标准的美国心血管疾病风险降低治疗资格：来自国家健康与营养检查调查的见解
Circ Cardiovasc Qual Outcomes. 2024 Jan;17(1):e010640. doi: 10.1161/CIRCOUTCOMES.123.010640. Epub 2023 Nov 11.
4
US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events.美国人群的资格以及司美格鲁肽治疗对肥胖患病率和心血管疾病事件的估计影响。
Cardiovasc Drugs Ther. 2025 Feb;39(1):75-84. doi: 10.1007/s10557-023-07488-3. Epub 2023 Aug 14.
5
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.